ROCKVILLE, Md. (AP) — Human Genome Sciences Inc. has asked the FDA to approve ABthrax, a drug it is developing to treat inhaled anthrax. Human Genome Sciences submitted a Biologics License Application for ABthrax, or raxibacumab. The company is developing the drug for emergency use, such as a bioterrorist attack. Human Genome Sciences delivered 20,000 doses of the drug to the U.S. Strategic National Stockpile in the first quarter. The company will received $10 million from the U.S. government if the FDA approves the drug.
